Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;58(9):1048-1050.
doi: 10.1038/s41409-023-02016-1. Epub 2023 Jun 17.

CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas

Katharina Baur  1   2 , Andreas Buser  3   4   5 , Lukas T Jeker  4   6   7 , Nina Khanna  4   6   8 , Heinz Läubli  4   6   9 , Dominik Heim  3 , Jan C Dirks  10 , Corinne C Widmer  3   10 , Thomas Volken  11 , Jakob R Passweg  3   4 , Andreas Holbro  3   4   5
Affiliations

CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas

Katharina Baur et al. Bone Marrow Transplant. 2023 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

LTJ is a co-founder and board member of and holds equity in Cimeio Therapeutics AG a biotech company developing engineered cellular therapies. LTJ’s activities related to Cimeio are unrelated to this study.

Figures

Fig. 1
Fig. 1. CAR T-cell expansion and association with response and therapy related toxicities.
a–c Course of expansion of total CAR T-cells, CD4 + CAR-T cells, and CD8 + CAR T-cells in the first 6 months after CAR T-cell infusion. d–g Comparison of CAR T and CD4 + CAR T AUC0-28d in blood of patients with or without CR and CRS at 1 month post transfusion Footnote: Horizontal line represents median, dot represents arithmetic mean.
See this image and copyright information in PMC

References

    1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531–44. doi: 10.1056/NEJMoa1707447. - DOI - PMC - PubMed
    1. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. 2022: JCO2102370. e-pub ahead of print 20220604; 10.1200/JCO.21.02370. - PMC - PubMed
    1. Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017;130:2317–25. doi: 10.1182/blood-2017-06-786129. - DOI - PMC - PubMed
    1. Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood. 2021;137:323–35. doi: 10.1182/blood.2020006770. - DOI - PMC - PubMed
    1. Sarikonda G, Pahuja A, Kalfoglou C, Burns K, Nguyen K, Ch’en IL, et al. Monitoring CAR-T cell kinetics in clinical trials by multiparametric flow cytometry: Benefits and challenges. Cytom B Clin Cytom. 2021;100:72–78. doi: 10.1002/cyto.b.21891. - DOI - PubMed

Publication types